Las Vegas Sands (NYSE: LVS) CEO discloses major option exercises and share sales

Rhea-AI Filing Summary

Las Vegas Sands Corp. reported insider transactions by Chairman and CEO Robert Goldstein. On December 12, 2025, he exercised options to acquire 15,489 common shares at $50.33 per share and sold the same number at a weighted average price of $66.24. On December 15, 2025, he exercised options to acquire 734,511 shares at $50.33 and sold 732,186 shares at a weighted average price of $66.8, followed by an additional sale of 2,325 shares at a weighted average price of $67.28, leaving him with no directly held common shares after these transactions. Beneficial ownership includes 129,005 shares held indirectly through The Robert and Sheryl Goldstein Trust, as well as vested options to purchase 1,250,000 shares and 403,800 unvested restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldstein Robert G

(Last) (First) (Middle)

5420 S. DURANGO DRIVE

(Street)

LAS VEGAS NV 89113

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAS VEGAS SANDS CORP [ LVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		15,489	A	$50.33	15,489	D
Common Stock	12/12/2025		S		15,489	D	$66.24(1)	0	D
Common Stock	12/15/2025		M		734,511	A	$50.33	734,511	D
Common Stock	12/15/2025		S		732,186	D	$66.8(2)	2,325	D
Common Stock	12/15/2025		S		2,325	D	$67.28(3)	0	D
Common Stock								129,005	I	By The Robert and Sheryl Goldstein Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$50.33	12/12/2025		M			15,489	(4)	11/19/2028	Common Stock	15,489	$0	1,984,511	D
Option (Right to Buy)	$50.33	12/15/2025		M			734,511	(4)	11/19/2028	Common Stock	734,511	$0	1,250,000	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00 to $66.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.27 to $67.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.27 to $67.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The options vested as follows: 500,000 on January 1, 2021, 500,000 on January 1, 2022, 500,000 on January 1, 2023, 500,000 on January 1, 2024, and 500,000 on December 31, 2024.

Remarks:

In addition to the options exercised and the underlying shares sold on December 12, 2025 and December 15, 2025, Mr. Goldstein holds options to purchase 1,250,000 shares that are vested and 403,800 restricted stock units that are unvested.

	/s/ Judy Tomkins, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Las Vegas Sands (LVS) report for its CEO?

The report shows Chairman and CEO Robert Goldstein exercised stock options and sold the underlying common shares on December 12, 2025 and December 15, 2025, resulting in no directly held common shares after these transactions.

How many Las Vegas Sands shares did the CEO sell in December 2025?

On December 12, 2025, Robert Goldstein sold 15,489 shares at a weighted average price of $66.24. On December 15, 2025, he sold 732,186 shares at a weighted average price of $66.8 and an additional 2,325 shares at a weighted average price of $67.28.

At what price did the Las Vegas Sands CEO exercise his stock options?

Robert Goldstein exercised options to acquire Las Vegas Sands common stock at an exercise price of $50.33 per share on both December 12, 2025 (15,489 shares) and December 15, 2025 (734,511 shares).

What Las Vegas Sands equity does the CEO continue to hold after these trades?

After the reported trades, Robert Goldstein has no directly held common shares but beneficial ownership includes 129,005 shares held indirectly through The Robert and Sheryl Goldstein Trust, vested options to purchase 1,250,000 shares, and 403,800 unvested restricted stock units.

When do the reported Las Vegas Sands options held by the CEO expire?

The options referenced in the transactions have an expiration date of November 19, 2028, and the footnote explains that the original grant vested in five tranches between January 1, 2021 and December 31, 2024.